Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

F FROMM

Showing results (171-180 of 247) with videos related to

Pageof 25
Sort By:
The Journal of Clinical Investigation|February 7, 1998
The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitorsR B Kim, M F Fromm, C Wandel, et al.
Pharmacogenetics|July 4, 2001
The C3435T mutation in the human MDR1 gene is associated with altered efflux of the P-glycoprotein substrate rhodamine 123 from CD56+ natural killer cellsM Hitzl, S Drescher, H van der Kuip, et al.
Journal of Clinical Medicine|January 8, 2023
Documentation of Drug-Related Problems with ICD-11: Application of the New WHO Code-Set to Clinical Routine DataWahram Andrikyan, Lea Jung-Poppe, Anna Altenbuchner, et al.
Biochemical Pharmacology|August 28, 2010
Influence of the flavonoids apigenin, kaempferol, and quercetin on the function of organic anion transporting polypeptides 1A2 and 2B1Kathrin Mandery, Krystyna Bujok, Ingrid Schmidt, et al.
Naunyn-Schmiedeberg'S Archives of Pharmacology|August 13, 2002
Pharmacokinetics of intravenous etoposide in patients with breast cancer: influence of dose escalation and cyclophosphamide and doxorubicin coadministrationDagmar Busse, Gudrun Würthwein, Christiane Hinske, et al.
Molecular Pharmaceutics|December 26, 2015
The Nonmetabolized β-Blocker Nadolol Is a Substrate of OCT1, OCT2, MATE1, MATE2-K, and P-Glycoprotein, but Not of OATP1B1 and OATP1B3Shingen Misaka, Jana Knop, Katrin Singer, et al.
Cardiovascular Diabetology|January 7, 2022
Effects of treatment with SGLT-2 inhibitors on arginine-related cardiovascular and renal biomarkersArne Gessner, Anna Gemeinhardt, Agnes Bosch, et al.
Pharmacogenetics|July 31, 2004
Lipid-lowering response to statins is affected by CYP3A5 polymorphismKari T Kivistö, Mikko Niemi, Elke Schaeffeler, et al.
Studies in Health Technology and Informatics|August 28, 2014
The effect object paradigm--a means to support medication safety with clinical decision supportAndrius Patapovas, Barbara Pfistermeister, Aleksey Tarkhov, et al.
Pharmacogenetics and Genomics|June 14, 2008
Disposition of ezetimibe is influenced by polymorphisms of the hepatic uptake carrier OATP1B1Stefan Oswald, Jörg König, Dieter Lütjohann, et al.
Pageof 25

Showing results (171-180 of 247) with videos related to

Sort By:
Pageof 25
The Journal of Clinical Investigation|February 7, 1998
The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitorsR B Kim, M F Fromm, C Wandel, et al.
Pharmacogenetics|July 4, 2001
The C3435T mutation in the human MDR1 gene is associated with altered efflux of the P-glycoprotein substrate rhodamine 123 from CD56+ natural killer cellsM Hitzl, S Drescher, H van der Kuip, et al.
Journal of Clinical Medicine|January 8, 2023
Documentation of Drug-Related Problems with ICD-11: Application of the New WHO Code-Set to Clinical Routine DataWahram Andrikyan, Lea Jung-Poppe, Anna Altenbuchner, et al.
Biochemical Pharmacology|August 28, 2010
Influence of the flavonoids apigenin, kaempferol, and quercetin on the function of organic anion transporting polypeptides 1A2 and 2B1Kathrin Mandery, Krystyna Bujok, Ingrid Schmidt, et al.
Naunyn-Schmiedeberg'S Archives of Pharmacology|August 13, 2002
Pharmacokinetics of intravenous etoposide in patients with breast cancer: influence of dose escalation and cyclophosphamide and doxorubicin coadministrationDagmar Busse, Gudrun Würthwein, Christiane Hinske, et al.
Molecular Pharmaceutics|December 26, 2015
The Nonmetabolized β-Blocker Nadolol Is a Substrate of OCT1, OCT2, MATE1, MATE2-K, and P-Glycoprotein, but Not of OATP1B1 and OATP1B3Shingen Misaka, Jana Knop, Katrin Singer, et al.
Cardiovascular Diabetology|January 7, 2022
Effects of treatment with SGLT-2 inhibitors on arginine-related cardiovascular and renal biomarkersArne Gessner, Anna Gemeinhardt, Agnes Bosch, et al.
Pharmacogenetics|July 31, 2004
Lipid-lowering response to statins is affected by CYP3A5 polymorphismKari T Kivistö, Mikko Niemi, Elke Schaeffeler, et al.
Studies in Health Technology and Informatics|August 28, 2014
The effect object paradigm--a means to support medication safety with clinical decision supportAndrius Patapovas, Barbara Pfistermeister, Aleksey Tarkhov, et al.
Pharmacogenetics and Genomics|June 14, 2008
Disposition of ezetimibe is influenced by polymorphisms of the hepatic uptake carrier OATP1B1Stefan Oswald, Jörg König, Dieter Lütjohann, et al.
Pageof 25